First global data, from Rosetta Lung-02 in first-line NSCLC, tell a familiar story.
ApexOnco Front Page
Recent articles
Silevertinib efficacy comes close to firmonertinib’s, but toxicity is a new worry.
New first-in-human trials include Kivu and Menarini projects acting on PKT7 and KIF18A.
An in vivo Car-T produced a 100% response rate – in three patients.
Data will be presented on Kura’s Komzifti and Syndax’s Revuforj in first-line AML.
Rival BTK degraders face off, as do bispecific Cars and T-cell engagers.
Five years after settling, GSK is again accused of breaching the Jemperli deal.
Arcellx and AstraZeneca take centre stage.